Grant of Options to Directors

Alliance Pharma PLC

05 October 2023

 

For immediate release

5 October 2023

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Grant of Options to Directors

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the Board has issued options over an aggregate of 2,281,643 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to the PDMRs detailed below, pursuant to the Company's Long-Term Incentive Plan 2019.

Peter Butterfield, Chief Executive Officer, has been awarded 851,666 share options.

Andrew Franklin, Chief Financial Officer, has been awarded 568,866 share options.

Jeyan Heper, Chief Operating Officer, has been awarded 861,111 share options (250,000 of which have been awarded pursuant to his joining of the Company earlier this year).

The awards have been granted at nil-cost and become exercisable on 4 October 2026 subject always to continued employment and the satisfaction of performance conditions based on EPS, TSR and ROCE targets.

The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:

Name	Share Options granted	Total no. of options over ordinary shares now held
Peter Butterfield	851,666	4,057,553
Andrew Franklin	568,866	2,845,373
Jeyan Heper	861,111	861,111

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by person discharging managerial responsibilities.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Peter Butterfield
2	Reason for the notification
a)	Position/status	Chief Executive Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.0 pence each ISIN: GB0031030819
b)	Nature of the transaction	Grant of Options
c)	Currency	GBP
d)	Price(s) and volume(s)	Exercise Price (p)	No. of share options
		Nil	851,666
e)	Aggregated information - Aggregated volume - Price - Aggregated total	Grant of 851,666  options to acquire ordinary shares of 1 pence each at nil-cost.
f)	Date of the transaction	4 October 2023
g)	Place of the transaction	Outside of trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Andrew Franklin
2	Reason for the notification
a)	Position/status	Chief Financial Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.0 pence each ISIN: GB0031030819
b)	Nature of the transaction	Grant of Options
c)	Currency	GBP
d)	Price(s) and volume(s)	Exercise Price (p)	No. of share options
		Nil	568,866
e)	Aggregated information - Aggregated volume - Price - Aggregated total	Grant of 568,866 options to acquire ordinary shares of 1 pence each at nil-cost.
f)	Date of the transaction	4 October 2023
g)	Place of the transaction	Outside of trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Jeyan Heper
2	Reason for the notification
a)	Position/status	Chief Operating Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.0 pence each ISIN: GB0031030819
b)	Nature of the transaction	Grant of Options
c)	Currency	GBP
d)	Price(s) and volume(s)	Exercise Price (p)	No. of share options
		Nil	861,111
e)	Aggregated information - Aggregated volume - Price - Aggregated total	Grant of 861,111options to acquire ordinary shares of 1 pence each at nil-cost.
f)	Date of the transaction	4 October 2023
g)	Place of the transaction	Outside of trading venue

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Head of Investor Relations: Cora McCallum	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
[e-mail]
Numis Securities Limited (Nominated Adviser and Joint Broker)	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc (Joint Broker)	+ 44 (0)20 7597 5970
Patrick Robb / Maria Gomez de Olea

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END